Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphoedema24.09.01.001; 01.09.01.0060.000168%
Lymphoma01.12.01.001; 16.20.01.0010.000224%Not Available
Lymphopenia01.02.02.0020.000884%Not Available
Macular oedema06.04.06.0050.000112%Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.0020.000112%Not Available
Metabolic acidosis14.01.01.0030.000448%Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.000672%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.000448%Not Available
Microangiopathic haemolytic anaemia24.03.02.019; 01.06.02.0020.000112%Not Available
Micturition urgency20.02.02.0060.000112%
Mouth haemorrhage24.07.02.014; 07.05.02.0010.000392%
Mouth ulceration07.05.06.0040.000280%Not Available
Mucosal inflammation08.01.06.0020.006111%Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle spasms15.05.03.004--
Myelodysplastic syndrome16.01.04.001; 01.10.04.0010.000750%
Myelopathy17.10.01.007--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia02.02.02.008; 24.04.04.0100.000336%Not Available
Myoclonus17.02.05.008--Not Available
Myositis15.05.01.0010.000112%
Nail dystrophy23.02.05.0030.000112%Not Available
Nausea07.01.07.0010.020046%
Neck pain15.03.04.0090.000616%
Necrosis24.04.02.006; 08.03.03.0010.000806%Not Available
Necrosis ischaemic24.04.02.0180.000112%Not Available
Nephrogenic diabetes insipidus20.05.03.010; 14.05.07.0020.000112%Not Available
Nephropathy20.05.03.0010.000112%Not Available
Nephropathy toxic20.05.03.002; 12.03.01.0100.000940%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene